CompletedNCT00999895
Official study titleA Non-interventional, Prospective, Open-label Study for the Evaluation of the Selection and Outcome of the Antipsychotic Treatment Switch in Outpatients With Schizophrenia - ETOS Study
This study has finished and is no longer accepting participants.
Multiple locations, including PátraiSchizophreniaObservational studyAges 18–65
- Countries
- Greece
- Sponsor
- AstraZeneca
CompletedNCT02947308
Official study titleA Longitudinal Study Examining Three RDoC Constructs in Adolescents With Non-Suicidal Self-Injury
This study has finished and is no longer accepting participants.
In MinneapolisSuicidalityObservational studyAges 12–16
- Countries
- United States
- Sponsor
- University of Minnesota
CompletedNCT00844857
What is this study about?Researchers compared Olanzapine Fluoxetine Combination (OFC) and placebo, tracking side effects to assess safety in people with bipolarity type I.
This study has finished and is no longer accepting participants.
Multiple locations, including San DiegoBipolarity, DepressionMedication studyAges 10–17
- Countries
- United States, Russia
- Sponsor
- Eli Lilly and Company
CompletedNCT00520923
What is this study about?Researchers compared LY2140023, placebo and Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BanfieldSchizophreniaMedication studyAges 18–65
- Countries
- Argentina, Austria, Croatia, + 6 others
- Sponsor
- Denovo Biopharma LLC
CompletedNCT00471354
About this title
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
Read the official source — NCT00471354Official study titleEvaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride
This study has finished and is no longer accepting participants.
Multiple locations, including BeijingADHDMedication studyAges 8–11
- Countries
- China, South Korea, Taiwan
- Sponsor
- Eli Lilly and Company
CompletedNCT03629951
Official study titleAn Observational Study for Schizophrenia Relapse Prediction
This study has finished and is no longer accepting participants.
Multiple locations, including AhmedabadSchizophreniaObservational studyAges 18–50
- Countries
- India
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT00195780
About this title
A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
Read the official source — NCT00195780Official study titleAn Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
This study has finished and is no longer accepting participants.
Multiple locations, including San DiegoBipolarityMedication studyAges 10–17
- Countries
- United States
- Sponsor
- Abbott
TerminatedNCT01127646
Official study titleAssessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)
This study ended early.
Multiple locations, including ArnhemADHDMedication studyAges 6–16
- Countries
- Netherlands, Spain, Sweden
- Sponsor
- Eli Lilly and Company
CompletedACTRN12626000361303
Official study titleA four-arm randomised controlled trial in Malaysia among caregivers of preschool children with autism comparing a one-day parent training workshop and WHO Caregiver Skills Training eLearning (alone and in combination) on parents' confidence and wellbeing, and children's behaviour and autism symptoms.
This study has finished and is no longer accepting participants.
In MalaysiaAnxiety, DepressionInterventional studyAges 30 months+
- Countries
- Malaysia
- Sponsor
- Ker Yung Chua, Sarawak General Hospital
CompletedNCT05841030
Official study titleA Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNRI
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamDepressionObservational studyAges 18–74
- Countries
- United States, France, Canada, + 8 others
- Sponsor
- Janssen Research & Development, LLC
UnknownNCT03642964
Official study titleA Phase 2a Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole IR, Given With Ondansetron in Patients With Major Depressive Disorder
Current recruitment status is unconfirmed.
In Long BeachDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Chase Therapeutics Corporation
CompletedNCT03854578
Official study titleA Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder
This study has finished and is no longer accepting participants.
In BerlinDepressionMedication studyAges 18–45
- Countries
- Germany
- Sponsor
- Boehringer Ingelheim